Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Interesting committee they've formed
View:
Post by Wino115 on Feb 16, 2023 11:09am

Interesting committee they've formed

Very interesting group put together for this stage.

- The Yale doctor is the one who trialed docetaxal through all three phases for prostate cancer. So a specialist in what taxols can do. Hopefully he can also tap into that Yale PDC connection.  So he might be the chemo bomb expert.

- The Texas doctor (who's Canadian actually) specializes almost exclusively in doing Phase 1 trials for oncology. He also started a cancer genome project, so I assume he might be the expert around the target and sort1, maybe toxicity and safety issues to.  Also perhaps dosing logic.

- The Tennesee doctor seems to be a leader in gynecological and overall research, she seems to be a leader in the conferences and has a lot of social media followers. Seems sort of an all around type.

We know the lead investigator is the MD Anderson women along with those other 3-4 clinics and then Rothemberg sheparded 3-4 oncology drugs for Pfizer.  

Seems like they have the key bases covered.
Comment by Trogarzon on Feb 16, 2023 11:29am
Maybe this draws interest from their followers... if they mention it of course on their Twitter accounts or in their Pharma networks maybe some Paul Levesque somewhere picks it up and gives our Paul a call to discuss a partnership... from rags to riches again.... who hoo...
Comment by palinc2000 on Feb 16, 2023 2:33pm
Interesting group indeed but we should not expect those Committee members to spend much time on this ...They will review the data submitted by THTX and come up with opinions/ recommendations as to the path forward .... Hard to imagine that they can provide anything other than : try this try that have you thought about this and about that It would be a lot more productive if there were a lot of ...more  
Comment by Wino115 on Feb 16, 2023 3:12pm
I wouldn't disagree with your conclusion. But when an effort is completely dependent on experimentation into the unknown, the value of someone who's traveled that path a few hundred times more than you have and has a far more developed knowledgebase about data hypothesis, comparative/similar approaches and what-ifs, that can be really valuable. If they signed on to help understand the key ...more  
Comment by palinc2000 on Feb 16, 2023 3:38pm
I do think that this step  with a Cimmittee is a necessary step especially given that in house experts is almost non existent.... While I dont hold my breath for a eureka moment I dont see much downside in going thru this exercise .
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities